These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 32866383)

  • 1. Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update.
    Wu T; Qin Z; Tian Y; Wang J; Xu C; Li Z; Bian J
    J Med Chem; 2020 Nov; 63(22):13228-13257. PubMed ID: 32866383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of Wogonin-based PROTACs against CDK9 and capable of achieving antitumor activity.
    Bian J; Ren J; Li Y; Wang J; Xu X; Feng Y; Tang H; Wang Y; Li Z
    Bioorg Chem; 2018 Dec; 81():373-381. PubMed ID: 30196207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of novel CDK 9 inhibitors based on virtual screening, molecular dynamics simulation, and biological evaluation.
    Wu M; Han J; Liu Z; Zhang Y; Huang C; Li J; Li Z
    Life Sci; 2020 Oct; 258():118228. PubMed ID: 32781071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Insights on Selective and Specific Inhibitors of Cyclin Dependent Kinase 9 Enzyme (CDK9) for the Purpose of Cancer Therapy.
    Karati D; Mahadik KSR; Trivedi P; Kumar D
    Anticancer Agents Med Chem; 2023; 23(4):383-403. PubMed ID: 35708082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CDK9 inhibitors in acute myeloid leukemia.
    Boffo S; Damato A; Alfano L; Giordano A
    J Exp Clin Cancer Res; 2018 Feb; 37(1):36. PubMed ID: 29471852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy.
    Sonawane YA; Taylor MA; Napoleon JV; Rana S; Contreras JI; Natarajan A
    J Med Chem; 2016 Oct; 59(19):8667-8684. PubMed ID: 27171036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological targeting of CDK9 in cardiac hypertrophy.
    Krystof V; Chamrád I; Jorda R; Kohoutek J
    Med Res Rev; 2010 Jul; 30(4):646-66. PubMed ID: 19757441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uncovering potential CDK9 inhibitors from natural compound databases through docking-based virtual screening and MD simulations.
    Singh P; Kumar V; Jung TS; Lee JS; Lee KW; Hong JC
    J Mol Model; 2024 Jul; 30(8):267. PubMed ID: 39012568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor.
    Wang B; Wu J; Wu Y; Chen C; Zou F; Wang A; Wu H; Hu Z; Jiang Z; Liu Q; Wang W; Zhang Y; Liu F; Zhao M; Hu J; Huang T; Ge J; Wang L; Ren T; Wang Y; Liu J; Liu Q
    Eur J Med Chem; 2018 Oct; 158():896-916. PubMed ID: 30253346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-based design of highly selective 2,4,5-trisubstituted pyrimidine CDK9 inhibitors as anti-cancer agents.
    Shao H; Foley DW; Huang S; Abbas AY; Lam F; Gershkovich P; Bradshaw TD; Pepper C; Fischer PM; Wang S
    Eur J Med Chem; 2021 Mar; 214():113244. PubMed ID: 33581551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CDK9 as an Appealing Target for Therapeutic Interventions.
    Eyvazi S; Hejazi MS; Kahroba H; Abasi M; Zamiri RE; Tarhriz V
    Curr Drug Targets; 2019; 20(4):453-464. PubMed ID: 30362418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A patent review of selective CDK9 inhibitors in treating cancer.
    Wu T; Wu X; Xu Y; Chen R; Wang J; Li Z; Bian J
    Expert Opin Ther Pat; 2023 Apr; 33(4):309-322. PubMed ID: 37128897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and preclinical profile of YK-2168, a differentiated selective CDK9 inhibitor in clinical development.
    Liu Y; Xu Z; Hu L; Xia L; Li Q; Zhou W; Chen Y; Li W; Jiang W; Zhu X; Gao X; Xia Y; Zhu Z; Chen S; Ding CZ
    Bioorg Med Chem Lett; 2024 Nov; 112():129941. PubMed ID: 39222890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and synthesis of novel imidazo[4,5-b]pyridine based compounds as potent anticancer agents with CDK9 inhibitory activity.
    Ghanem NM; Farouk F; George RF; Abbas SES; El-Badry OM
    Bioorg Chem; 2018 Oct; 80():565-576. PubMed ID: 30025343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perspective of cyclin-dependent kinase 9 (CDK9) as a drug target.
    Krystof V; Baumli S; Fürst R
    Curr Pharm Des; 2012; 18(20):2883-90. PubMed ID: 22571657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcriptional regulation and therapeutic potential of cyclin-dependent kinase 9 (CDK9) in sarcoma.
    Walker RL; Hornicek FJ; Duan Z
    Biochem Pharmacol; 2024 Aug; 226():116342. PubMed ID: 38848777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small molecule inhibitors of cyclin-dependent kinase 9 for cancer therapy.
    Alsfouk A
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):693-706. PubMed ID: 33632038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of a highly potent, selective and novel CDK9 inhibitor as an anticancer drug candidate.
    Li Y; Guo Q; Zhang C; Huang Z; Wang T; Wang X; Wang X; Xu G; Liu Y; Yang S; Fan Y; Xiang R
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3231-3237. PubMed ID: 28651979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of a novel and highly selective CDK9 kinase inhibitor (JSH-009) with potent antitumor efficacy in preclinical acute myeloid leukemia models.
    Wang L; Hu C; Wang A; Chen C; Wu J; Jiang Z; Zou F; Yu K; Wu H; Liu J; Wang W; Wang Z; Wang B; Qi Z; Liu Q; Wang W; Li L; Ge J; Liu J; Liu Q
    Invest New Drugs; 2020 Oct; 38(5):1272-1281. PubMed ID: 31872348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of selective CDK9 degraders with enhancing antiproliferative activity through PROTAC conversion.
    Qiu X; Li Y; Yu B; Ren J; Huang H; Wang M; Ding H; Li Z; Wang J; Bian J
    Eur J Med Chem; 2021 Feb; 211():113091. PubMed ID: 33338869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.